{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:03:47Z","timestamp":1763809427878},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.2515\/therapie\/2015024","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T06:45:50Z","timestamp":1434091550000},"page":"415-424","source":"Crossref","is-referenced-by-count":3,"title":["Suivi th\u00e9rapeutique de l\u2019acide valpro\u00efque chez l\u2019enfant : \u00e9tude prospective de l\u2019effet de l\u2019observance et du niveau \u00e9conomique sur les concentrations plasmatiques r\u00e9siduelles et les crises \u00e9pileptiques"],"prefix":"10.1016","volume":"70","author":[{"given":"Rim","family":"Charfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Lakhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anis","family":"Klouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Salouage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.2515\/therapie\/2015024_bb0175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2515\/therapie\/2010029","article-title":"Suivi th\u00e9rapeutique pharmacologique du valproate","volume":"65","author":"Bentu\u00e9-Ferrer","year":"2010","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2015024_bb0180","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0163-7258(92)90004-J","article-title":"Rational use of antiepileptic drug levels","volume":"54","author":"Theodore","year":"1992","journal-title":"Pharmacol Ther"},{"key":"10.2515\/therapie\/2015024_bb0185","first-page":"25","article-title":"Pharmacokinetics, drug interactions and tolerability of valproate","volume":"37","author":"DeVane","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.2515\/therapie\/2015024_bb0190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2710.1991.tb00317.x","article-title":"Influence of age and concurrent medication on steady-state valproic acid serum level-dose ratios in Japanese paediatric patients","volume":"16","author":"Yukawa","year":"1991","journal-title":"J Clin Pharm Ther"},{"key":"10.2515\/therapie\/2015024_bb0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00148581-200608020-00004","article-title":"Valproate as a mainstay of therapy for pediatric epilepsy","volume":"8","author":"Guerrini","year":"2006","journal-title":"Pediatr Drugs"},{"key":"10.2515\/therapie\/2015024_bb0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0531-5131(02)00457-0","article-title":"Patient-tailored antiepileptic drug therapy: predicting response to antiepileptic drugs","volume":"1244","author":"Perucca","year":"2002","journal-title":"International Congress Series"},{"issue":"5","key":"10.2515\/therapie\/2015024_bb0205","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring","volume":"44","author":"Warner","year":"1998","journal-title":"Clinical Chemistry"},{"issue":"1","key":"10.2515\/therapie\/2015024_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","article-title":"MDR1 gene expression in brain of patients with medically intractable epilepsy","volume":"36","author":"Tishler","year":"1995","journal-title":"Epilepsia"},{"issue":"16","key":"10.2515\/therapie\/2015024_bb0215","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1097\/00001756-199911080-00032","article-title":"Over-expression of P-glycoprotein in malformations of cortical development","volume":"10","author":"Sisodiya","year":"1999","journal-title":"NeuroReport"},{"issue":"9249","key":"10.2515\/therapie\/2015024_bb0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(00)03573-X","article-title":"Multidrug-resistance protein 1 in focal corticaldysplasia","volume":"357","author":"Sisodiya","year":"2001","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2015024_bb0225","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00007691-199107000-00006","article-title":"Valproic acid dosages necessary to maintain therapeutic concentrations in children","volume":"13","author":"Suzuki","year":"1991","journal-title":"Ther Drug Monit"},{"issue":"Suppl","key":"10.2515\/therapie\/2015024_bb0230","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1097\/00004714-199202001-00010","article-title":"Pharmacokinetics of valproate and carbamazepine","volume":"12","author":"Wilder","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.2515\/therapie\/2015024_bb0235","first-page":"11","article-title":"Therapeutic drug monitoring of valproic acid in pediatric epileptic patients","volume":"1","author":"Subash","year":"2011","journal-title":"International Bulletin of Drug Research"},{"issue":"2","key":"10.2515\/therapie\/2015024_bb0240","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.2515\/therapie\/2015024_bb0245","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1980.tb04300.x","article-title":"Carbamazepine intoxication due to triacetyl oleandomycin administration in epileptic patients","volume":"21","author":"Mesdjian","year":"1980","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2015024_bb0250","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/pgmj.61.715.401","article-title":"Drug compliance and seizure control in epileptic children","volume":"61","author":"Lisk","year":"1985","journal-title":"Postgraduate Medical Journal"},{"key":"10.2515\/therapie\/2015024_bb0255","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.1.5689.147","article-title":"Supervision of epileptic patients taking phenytoin","volume":"1","author":"Gibberd","year":"1970","journal-title":"Br Med J"},{"key":"10.2515\/therapie\/2015024_bb0260","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/adc.46.247.386","article-title":"Value of blood phenytoin estimation in management of childhood epilepsy","volume":"46","author":"Dawson","year":"1971","journal-title":"Arch Dis Child"},{"key":"10.2515\/therapie\/2015024_bb0265","first-page":"232","article-title":"The medical treatment of epilepsy: maintenance of drug therapy","volume":"8","author":"Livingston","year":"1979","journal-title":"Pediatr Ann"},{"issue":"7","key":"10.2515\/therapie\/2015024_bb0270","first-page":"136","article-title":"Drug compliance and therapeutic consideration in 75 black epileptic children","volume":"24","author":"Frieman","year":"1978","journal-title":"Cent Afr J Med"},{"key":"10.2515\/therapie\/2015024_bb0275","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archneur.1974.00490410037002","article-title":"Anticonvulsant effect of diphenylhydantoin relative to plasma levels","volume":"31","author":"Lund","year":"1974","journal-title":"Arch Neurol"},{"key":"10.2515\/therapie\/2015024_bb0280","article-title":"Drug treatment of epilepsy","volume":"2","author":"Reynolds","year":"1978","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2015024_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.30.1.1","article-title":"Sodium valproate: pharmacokinetics and effectiveness in treating intractable seizures","volume":"30","author":"Redenbaugh","year":"1980","journal-title":"Neurology"},{"issue":"Suppl 4","key":"10.2515\/therapie\/2015024_bb0290","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1528-1157.1994.tb05951.x","article-title":"Standard approach to anticonvulsant drug treatment in the United States","volume":"35","author":"Pellock","year":"1994","journal-title":"Epilepsia"},{"issue":"3","key":"10.2515\/therapie\/2015024_bb0295","article-title":"Valproic acid in the treatment of pediatric seizures","volume":"3","author":"Marcia","year":"1997","journal-title":"Pediatric Pharmacotherapy"},{"key":"10.2515\/therapie\/2015024_bb0300","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate:a review after 35 years of use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2015024_bb0305","year":"2003"},{"key":"10.2515\/therapie\/2015024_bb0310","first-page":"1733","article-title":"Incidence of hypofibrinogenemia under valproate. Could it allow the detection of hepatotoxicity of this drug?","volume":"15","author":"Coquerel","year":"1986","journal-title":"Presse Med"},{"key":"10.2515\/therapie\/2015024_bb0315","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM197904263001706","article-title":"Acute hepatic failure associated with the use of sodium valproate-report of two fatal cases","volume":"300","author":"Suchy","year":"1979","journal-title":"New Engl J Med"},{"key":"10.2515\/therapie\/2015024_bb0320","first-page":"477","article-title":"Fatal hepatic failure and sodium valproate","volume":"6","author":"Le Bihan","year":"1982","journal-title":"Gastroenterol Clin Biol"},{"key":"10.2515\/therapie\/2015024_bb0325","series-title":"Drug Facts and Comparisons","first-page":"284c-h","article-title":"Valproic acid and derivatives","year":"1997"},{"key":"10.2515\/therapie\/2015024_bb0330","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002018-199615060-00003","article-title":"A comparative review of the adverse effects of anticonvulsants in children with epilepsy","volume":"15","author":"Wallace","year":"1996","journal-title":"Drug Safety"},{"key":"10.2515\/therapie\/2015024_bb0335","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/000992289503400810","article-title":"Necrotizing pancreatitis after 10 years of therapy with valproic acid","volume":"34","author":"Tobias","year":"1995","journal-title":"Clin Pediatr"},{"key":"10.2515\/therapie\/2015024_bb0340","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2515\/therapie:2004021","article-title":"Drug-induced parkinson syndromes","volume":"59","author":"Nguyen","year":"2004","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2015024_bb0345","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.47.3.626","article-title":"Reversible parkinsonism and cognitive impairment with chronic valproate use","volume":"47","author":"Armon","year":"1996","journal-title":"Neurology"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571631085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571631085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T09:58:59Z","timestamp":1599127139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571631085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S004059571631085X"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2015024","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}